VANDERBILT UNIVERSITY MEDICAL CENTER
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1925-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.vumc.org
Diagnosing Natriuretic Peptide Deficiency
- First Posted Date
- 2017-01-30
- Last Posted Date
- 2019-06-20
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT03035929
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Theophylline Treatment for Pseudohypoparathyroidism
Phase 2
Recruiting
- Conditions
- PseudohypoparathyroidismAlbright Hereditary Osteodystrophy
- Interventions
- Drug: Placebos
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 34
- Registration Number
- NCT03029429
- Locations
- 🇺🇸
Ashley Shoemaker, Nashville, Tennessee, United States
Noradrenergic and Stress-Related Etiologies of Chronic Fatigue Syndrome
Not Applicable
Completed
- Conditions
- Chronic Fatigue Syndrome
- Interventions
- Other: Posture Study, Autonomic Function Tests, and a Stress Test
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2018-04-26
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 55
- Registration Number
- NCT03029377
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Autonomic Blockade and Endogenous Glucose Production
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2021-06-08
- Lead Sponsor
- Vanderbilt University Medical Center
- Registration Number
- NCT03028571
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Preventing Hypoxemia With Manual Ventilation During Endotracheal Intubation (PreVent) Trial
Not Applicable
Completed
- Conditions
- Respiratory Failure With HypoxiaRespiratory FailureEndotracheal Intubation
- Interventions
- Other: No Manual VentilationOther: Manual Ventilation
- First Posted Date
- 2017-01-20
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 401
- Registration Number
- NCT03026322
- Locations
- 🇺🇸
Ochsner Health System, New Orleans, Louisiana, United States
🇺🇸The University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Louisiana State University School of Medicine, New Orleans, Louisiana, United States
Pharmacogenomics of the Variability in the In Vivo Response to Glucocorticoids
- First Posted Date
- 2017-01-18
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT03023891
- Locations
- 🇺🇸
Vanderbilt University Medical Center -CRC, Nashville, Tennessee, United States
Palliative Care for Non-Malignant Diseases (COMPASS Trial)
Not Applicable
Terminated
- Conditions
- Liver DiseasesLiver CirrhosisNASH (Non-Alcoholic Steatohepatitis)
- Interventions
- Other: Comprehensive Palliative Care servicesOther: Usual hepatic care
- First Posted Date
- 2017-01-16
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 63
- Registration Number
- NCT03022630
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Racial Differences in Vagal Control of Glucose Homeostasis, Chronic Study
Phase 1
Withdrawn
- Conditions
- Insulin SensitivityOxidative Stress
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-01-09
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- Vanderbilt University Medical Center
- Registration Number
- NCT03014323
- Locations
- 🇺🇸
Cyndya Shibao, Nashville, Tennessee, United States
CD36 in Nutrient Delivery and Its Dysfunction
Phase 1
Completed
- Conditions
- Insulin ResistanceEndothelial Dysfunction
- Interventions
- First Posted Date
- 2017-01-06
- Last Posted Date
- 2022-11-30
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 26
- Registration Number
- NCT03012386
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2
Phase 2
Withdrawn
- Conditions
- Heart Failure NYHA Class IIIHeart Failure NYHA Class IIHeart Failure NYHA Class I
- Interventions
- Drug: Sacubitril-Valsartan 200 mg bidDrug: Placebo
- First Posted Date
- 2016-12-29
- Last Posted Date
- 2018-01-11
- Lead Sponsor
- Vanderbilt University Medical Center
- Registration Number
- NCT03005184
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
© Copyright 2025. All Rights Reserved by MedPath